Publication:
GLP-1 and dual GIP/GLP-1 receptor agonists in overweight/obese patients for atherosclerotic cardiovascular disease prevention: Where are we now?

Simple item page
dc.contributor.authorRizzo, Manfredi
dc.date.accessioned2024-03-27T06:27:40Z
dc.date.available2024-03-27T06:27:40Z
dc.date.issued2023
dc.description.abstractIntroduction: Obesity is a highly prevalent chronic disease characterized by an increase of body fat stores.1 Increased adiposity (body fat), particularly abdominal/visceral fat, plays a role in altering immune and inflammatory function, developing insulin resistance (IR) and contributing to downstream metabolic risk factors (RFs) such as hyperglycemia, dyslipidemia, systemic adrenergic activity, hypertension, atherosclerosis and finally, cardiovascular (CV) disease (CVD).2 Furthermore, visceral fat is strongly associated with increased atherosclerotic burden and the risk of recurrent atherosclerotic CVD (ASCVD), residual CV risk, and CVD mortality.en_US
dc.identifier.other204-2023.164
dc.identifier.urihttps://repository.mbru.ac.ae/handle/1/1439
dc.language.isoenen_US
dc.subjectGlucagon-like peptide 1 receptor agonistsen_US
dc.subjectDual glucagon-like peptide 1/gastric inhibitoryen_US
dc.subjectPeptide receptor agonistsen_US
dc.subjectAtherosclerotic cardiovascular diseaseen_US
dc.subjectOverweighten_US
dc.subjectObesityen_US
dc.titleGLP-1 and dual GIP/GLP-1 receptor agonists in overweight/obese patients for atherosclerotic cardiovascular disease prevention: Where are we now?en_US
dc.typeArticleen_US
dspace.entity.typePublicationen_US

Files

Collections

Faculty Publications (CoM)